Skip to main content
ATOSSA THERAPEUTICS, INC. logo

ATOSSA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ATOS ISIN · US04962H5063 US Manufacturing
Open in API
Filings indexed 622 across all filing types
Latest filing 2015-11-12 Interim / Quarterly Rep…
Country US United States of America
Listing US ATOS

About ATOSSA THERAPEUTICS, INC.

https://atossatherapeutics.com/

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative medicines for areas of significant unmet medical need, with a primary focus on oncology. The company is dedicated to addressing the full continuum of breast cancer care. Its lead program is centered on (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen through clinical development for multiple breast cancer indications, including metastatic disease, aiming to provide a therapeutic with a potentially improved efficacy and tolerability profile.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2015
2015-11-12 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 12, 2015, for Atossa Genetics Inc. It announces the issuance of a press release regarding third quarter 2015 financial results and a company update. The document explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference. The text clarifies that the information is not "filed" for certain regulatory purposes and is primarily an announcement of the release of financial results rather than the detailed financial report itself. The document length is 3156 characters, which is relatively short and consistent with an announcement rather than a full financial report. Therefore, this filing is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results and attaching a press release, not the full earnings release or quarterly report itself.
2015-11-12 English
8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 28, 2015, by Atossa Genetics Inc. The content focuses on a notice from NASDAQ regarding the company's non-compliance with the minimum bid price requirement for continued listing. It discusses the potential delisting risk and the company's plan to regain compliance. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is a regulatory announcement about the listing status of the company's stock. Given the nature of the content and the form type (8-K), this fits the category of a Delisting Announcement (DLST). The document length is 4046 characters, which is sufficient to contain substantive information about the delisting notice rather than just a brief announcement or a certification. Therefore, the classification is DLST with high confidence.
2015-10-02 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 1, 2015, reporting the appointment of Scott Youmans as Chief Operating Officer of Atossa Genetics Inc. The content focuses on management changes, including details of the appointment, compensation, and indemnification agreement. There is no financial data or report content, only an announcement of a management change. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is about 4933 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the correct classification is MANG with high confidence.
2015-09-04 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-09-04 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-09-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.